Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3238/arztebl.2018.0175 http://scihub22266oqcxt.onion/10.3238/arztebl.2018.0175 C5913576!5913576!29607803     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29607803.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Dtsch+Arztebl+Int 2018 ; 115 (11): 175-81 Nephropedia Template TP {{tp|p=29607803|t=2018. Molecular Imaging in Oncology Using Positron Emission Tomography |pdf=|usr=}}{{29607803}} gab.com Text Molecular Imaging in Oncology Using Positron Emission Tomography JO: Dtsch Arztebl Int http://www.kidney.de/pget.php?&tw=1&pmid=29607803 #FOAvip Background: Anatomical and molecular data can be acquired simultaneously through the use of positron emission tomography (PET) in combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a hybrid technique. A variety of radiopharmaceuticals can be used to characterize various metabolic processes or to visualize the expression of receptors, enzymes, and other molecular target structures. Methods: This review is based on pertinent publications retrieved by a selective search in PubMed, as well as on guidelines from Germany and abroad and on systematic reviews and meta-analyses. Results: Established radiopharmaceuticals for PET, such as 2-[18F]fluoro-2-deoxyglucose ([18F]FDG), enable the visualization of physiological processes on the molecular level and can provide vital information for clinical decision-making. For example, PET can be used to evaluate pulmonary nodules for malignancy with 95% sensitivity and 82% specificity. It can be used both for initial staging and for the guidance of further treatment. Alongside the PET radiopharmaceuticals that have already been well studied and evaluated, newer ones are increasingly becoming available for the noninvasive phenotyping of tumor diseases, e.g., for analyzing the expression of prostate-specific membrane antigen (PSMA), of somatostatin receptors, or of chemokine receptors on tumor cells. Conclusion: PET is an important component of diagnostic algorithms in oncology. It can help make diagnosis more precise and treatment more individualized. An increasing number of PET radiopharmaceuticals are now expanding the available options for imaging. Many radiopharmaceuticals can be used not only for non-invasive analysis of the expression of therapeutically relevant target structures, but also for the ensuing, target-directed treatment with radionuclides. Twit Text FOAVip Molecular Imaging in Oncology Using Positron Emission Tomography ????Dtsch Arztebl Int http://www.kidney.de/pget.php?&tw=1&pmid=29607803 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29607803 #FOAvip English Wikipedia <ref>{{Cite pmid|29607803}}</ref> Molecular Imaging in Oncology Using Positron Emission Tomography #MMPMID29607803 Derlin T; Grünwald V; Steinbach J; Wester HJ; L. Ross T Dtsch Arztebl Int 2018[Mar]; 115 (11): 175-81 PMID29607803show ga Background: Anatomical and molecular data can be acquired simultaneously through the use of positron emission tomography (PET) in combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a hybrid technique. A variety of radiopharmaceuticals can be used to characterize various metabolic processes or to visualize the expression of receptors, enzymes, and other molecular target structures. Methods: This review is based on pertinent publications retrieved by a selective search in PubMed, as well as on guidelines from Germany and abroad and on systematic reviews and meta-analyses. Results: Established radiopharmaceuticals for PET, such as 2-[18F]fluoro-2-deoxyglucose ([18F]FDG), enable the visualization of physiological processes on the molecular level and can provide vital information for clinical decision-making. For example, PET can be used to evaluate pulmonary nodules for malignancy with 95% sensitivity and 82% specificity. It can be used both for initial staging and for the guidance of further treatment. Alongside the PET radiopharmaceuticals that have already been well studied and evaluated, newer ones are increasingly becoming available for the noninvasive phenotyping of tumor diseases, e.g., for analyzing the expression of prostate-specific membrane antigen (PSMA), of somatostatin receptors, or of chemokine receptors on tumor cells. Conclusion: PET is an important component of diagnostic algorithms in oncology. It can help make diagnosis more precise and treatment more individualized. An increasing number of PET radiopharmaceuticals are now expanding the available options for imaging. Many radiopharmaceuticals can be used not only for non-invasive analysis of the expression of therapeutically relevant target structures, but also for the ensuing, target-directed treatment with radionuclides. äMolecular Imaging in Oncology Using Positron Emission Tomography (epmc).pdf DeepDyve Pubget Overpricing